Clinical Development Clinical Research Containment Licensing 
XTalks
APRIL 24, 2023
“Rare disease clinical trials are complex due to the additional scientific, medical, operational and regulatory requirements of newly emerging advanced therapies, such as gene therapy,” says Dr. Terence Eagleton, MB BS, Senior Medical Director at the global clinical research organization (CRO) Medpace.
The Pharma Data
JANUARY 24, 2021
Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration (“FDA”) approval. PharmaDrug Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
FEBRUARY 16, 2023
GCP is the international ethical and scientific quality standard for clinical trials that all clinical researchers need to follow. The clinical trial remains ongoing with other sites not operated by the third party, and Pfizer continues to enroll new participants at those sites.
The Pharma Data
DECEMBER 14, 2020
The Company anticipates using net proceeds from the offering to fund the continued development of ublituximab and umbralisib, the potential in-license, acquisition, development and commercialization of other pharmaceutical products, and for general corporate purposes. Morgan Securities LLC, Goldman Sachs & Co.
The Pharma Data
JANUARY 14, 2021
Associate Professor of Medicine at UCLA, Co-director of the Gastrointestinal Oncology Program and Director of Early Phase Clinical Research at the Jonsson Comprehensive Cancer Center. Bemarituzumab is being developed in gastric and GEJ cancer as a targeted therapy for tumors that overexpress FGFR2b. Wainberg, M.D.,
The Pharma Data
OCTOBER 27, 2020
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. Upon option exercise, Novartis would be responsible for all further development and commercialization activities.
The Pharma Data
NOVEMBER 30, 2020
“I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, as well as the staff at clinical trial sites who have been on the front lines of the fight against the virus. These medically high-risk groups represent 42% of the total participants in the Phase 3 COVE study. Department of Defense Contract No.
Expert insights. Personalized for you.
95 
Let's personalize your content